HBW US Executive Decisions: Engle Leaves FTC, Changes At Nature's Bounty, CRN And Benev

Mary Engle led FTC enforcement actions including against POM Wonderful’s claims for its pomegranate supplements; Huber is CRN’s scientific and regulatory affairs VP and Amanda Darlington is government relations director; Jones takes charge of Nature’s Bounty supply chain; and Benev Co. names five aesthetic experts to Medical Advisory Board to advance its “medically developed cosmeceutical line.”

Handshake of businessmen

Mary Engle is retiring from the Federal Trade Commission after 30 years, including serving as the Division of Advertising Practices associate director introducing and explaining commission regulations on responsibilities for dietary supplement and other consumer product firms to support advertising claims. The commission on 21 January said Engle since 2001 has been associate director in the Bureau of Consumer Protection’s advertising practices unit. In that post, she oversaw the bureau’s work regarding national advertising policy and law enforcement, including claims made about food, supplements, alcohol, tobacco and broadband as well as digital technology marketing practices, such as native advertising and influencer marketing.

Engle has led FTC enforcement actions including against POM Wonderful LLC’s claims and other advertising for its pomegranate supplements. (Also see "Supreme Court Slays POM Wonderful's Appeal Of FTC Order" - HBW Insight, 3 May, 2016.) Other enforcements under her lead included the commission’s first case involving social media influencers against high-end fashion retailer Lord & Taylor – a topic that also resonates in the consumer health and beauty product sectors

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

People On The Move: Appointments At ANEPF, Inula, Opella

 
• By 

A round-up of the latest consumer health people moves: ANEFP elects president; Inula Group appoints CEO; Opella names ANZ head.

In Blistering Criticism, Health Subcommittee Democrat Warns Of Kennedy’s ‘Toxic Brew’ Plans

 

Trump’s first-term public health appointees “were serious people doing serious work in a bipartisan nature,” but HHS Secretary Robert F. Kennedy and other current presidential advisors “are not serious people,” says Massachusetts’ Jake Auchincloss.

MAHA Translates To ‘Change The Broken System’ At US FDA For Commissioner Makary

 

Among FDA's diversions from accepted practices is not going “through the bureaucracy” of advisory committees for experts’ input on potential changes to improve the safety and nutrition profile of food products, says Commissioner Martin Makary.

Commissioner Makary Outlines Expectations For US FDA: ‘Challenge Deeply Held Assumptions’

 

“It was a little hard to begin after the change or the reduction in force. We're doing everything we can to do an assessment, restore some services of individuals, and also try to rebuild the culture, because it is a great culture,” says FDA Commissioner Martin Makary during FDLI conference.

More from HBW Insight

Green Guides Update, FTC Enforcement In ‘Deregulatory’ Environment – BBB National Programs’ Engle During IBA Conference

 

The FTC’s Green Guides proposed update was expected by the end of the Biden Administration and there’s no indication it will be unveiled soon, says Mary Engle, BBB National Programs Exec VP, Policy. She also discussed the importance of industry self-regulation of artificial intelligence.

MAHA Translates To ‘Change The Broken System’ At US FDA For Commissioner Makary

 

Among FDA's diversions from accepted practices is not going “through the bureaucracy” of advisory committees for experts’ input on potential changes to improve the safety and nutrition profile of food products, says Commissioner Martin Makary.

Value Of Consumer Wearables Within The Clinic Currently Unknown, Says Cardiologist

 

“It’s quite likely [consumer wearable manufacturers] are changing the sensitivity and specificity based on consumer feedback, but not for medical reasons,” said Dipak Kotecha, a University of Birmingham professor of cardiology. Often, self-reported performance evidence from manufacturers is “low quality and biased.”